主页 > 医学新闻 >
【Blood】1514例接受造血干细胞移植患者发生静脉
The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation:
implications for VTE prevention
David E. Gerber,1 Jodi B. Segal,2 M. Yair Levy,3 Joyce Kane,4 Richard J. Jones,3 and Michael B. Streiff5
1Venous thromboembolism (VTE) is increasingly diagnosed among individuals with hematologic malignancies. However, the risk of VTE among patients undergoing hematopoietic stem cell transplantation (HSCT) is unclear. We examined the incidence and risk factors for VTE and bleeding among 1514 patients undergoing
in-patient HSCT. No protocolized VTE prophylaxis was used. By HSCT day 180, 75 symptomatic VTE occurred in 70 patients (4.6%; 95% confidence interval [CI], 3.6%-5.8%). Fifty-five (3.6%) were catheterassociated, 11 (0.7%) were non–catheterassociated deep venous thromboses, and 9 (0.6%) were pulmonary emboli. Hirtyfour percent of VTE occurred at a platelet count less than 50 _109/L; 13% occurred at a platelet count less than 20 _109/L. In multivariate analysis, VTE was associated with prior VTE (odds ratio [OR], 2.9; 95% CI, 1.3-6.6) and with graft-versushost disease (GVHD; OR, 2.4; 95% CI, 1.4-4.0). Clinically significant bleeding occurred in 230 patients (15.2%; 95% CI, 13.4%-17.1%); 55 patients (3.6%; 95% CI, 2.7%-4.7%) had fatal bleeding. Bleeding was associated with anticoagulation (OR, 3.1; 95% CI, 1.8-5.5), GVHD (OR, 2.4; 95% CI, 1.8-3.3), and veno-occlusive disease (OR, 2.2; 95% CI, 1.4-3.6). In HSCT patients, VTE is primarily catheter-related and 3-fold less common than clinically significant bleeding. These findings warrant
consideration when selecting VTE prophylaxis in HSCT patients. (Blood.2008;112:504-510) 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。
implications for VTE prevention
Venous thromboembolism (VTE) is increasingly diagnosed among individuals with hematologic malignancies. However, the risk of VTE among patients undergoing hematopoietic stem cell transplantation (HSCT) is unclear. We examined the incidence and risk factors for VTE and bleeding among 1514 patients undergoing in-patient HSCT. No protocolized VTE prophylaxis was used. By HSCT day 180, 75 symptomatic VTE occurred in 70 patients (4.6%; 95% confidence interval [CI], 3.6%-5.8%). Fifty-five (3.6%) were catheterassociated, 11 (0.7%) were non–catheterassociated deep venous thromboses, and 9 (0.6%) were pulmonary emboli. Hirtyfour percent of VTE occurred at a platelet count less than 50 _109/L; 13% occurred at a platelet count less than 20 _109/L. In multivariate analysis, VTE was associated with prior VTE (odds ratio [OR], 2.9; 95% CI, 1.3-6.6) and with graft-versushost disease (GVHD; OR, 2.4; 95% CI, 1.4-4.0). Clinically significant bleeding clinically significant bleeding 应翻译成活动性出血
找到一个例句：
They had a platelet count of less than 30×10~9/L or clinically significant bleeding.
血小板计数低于30×109~9／L或有活动性出血。 Venous thromboembolism (VTE)应该翻译为：静脉血栓栓塞。目前认为深静脉血栓形成（deep venous thrombosis，DVT）与肺血栓栓塞（pulmonary thromboembolism，ＰＴＥ）是同一个疾病的不同发展阶段。由于肺血栓栓塞(PTE)的栓子主要来自深静脉血栓(DVT)，另一方面，DVT常引起PE，两者密不可分，故人们将两者合称为静脉血栓栓塞症(VTE)。
附一篇较早发表于《中华内科杂志》关于ＶＴＥ的综述。
我国静脉血栓栓塞症的研究现状[1].pdf (98.62k)
lyong74 wrote:
Venous thromboembolism (VTE)应该翻译为：静脉血栓栓塞。目前认为深静脉血栓形成（deep venous thrombosis，DVT）与肺血栓栓塞（pulmonary thromboembolism，ＰＴＥ）是同一个疾病的不同发展阶段。由于肺血栓栓塞(PTE)的栓子主要来自深静脉血栓(DVT)，另一方面，DVT常引起PE，两者密不可分，故人们将两者合称为静脉血栓栓塞症(VTE)。
附一篇较早发表于《中华内科杂志》关于ＶＴＥ的综述。
[标签:content1][标签:content2]阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-04-19 17:14
医学,生命科学网